Ascletis Pharma Inc. (ASCLF)
OTCMKTS
· Delayed Price · Currency is USD
1.250
0.00 (0.00%)
At close: Jul 7, 2025
Ascletis Pharma Revenue
In the year 2024, Ascletis Pharma had annual revenue of 1.28M CNY, down -97.73%. Ascletis Pharma had revenue of 1.28M in the half year ending December 31, 2024, a decrease of -91.92%.
Revenue
1.28M CNY
Revenue Growth
-97.73%
P/S Ratio
6,182.53
Revenue / Employee
5.55K CNY
Employees
231
Market Cap
1.09B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.28M | -55.31M | -97.73% |
Dec 31, 2023 | 56.60M | 2.51M | 4.63% |
Dec 31, 2022 | 54.09M | -22.79M | -29.64% |
Dec 31, 2021 | 76.88M | 41.88M | 119.64% |
Dec 31, 2020 | 35.00M | -138.44M | -79.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Ascletis Pharma News
- 8 days ago - Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30 - PRNewsWire
- 23 days ago - Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis - PRNewsWire
- 4 weeks ago - Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) - PRNewsWire
- 5 weeks ago - Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints - PRNewsWire
- 7 weeks ago - Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis - PRNewsWire
- 7 weeks ago - Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity - PRNewsWire
- 2 months ago - Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity - PRNewsWire
- 2 months ago - Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA - PRNewsWire